EMA accepts The Medicines Co.'s application for urinary tract infection drug | S&P Global Market Intelligence

WORKFLOW SOLUTIONS
PRODUCTS
See More S&P Global Solutions
CONTENT
SECTOR-SPECIFIC INSIGHTS
More ways we can help
NEWS & RESEARCH TOPICS
See More
Featured Events
Hosted EventsThe Future of Credit and Risk Management: Trends, Challenges, and Opportunities in Europe
- 03/28/2023
- CIRCL, Amsterdam
- 08:30 - 13:00 Central European Time
WebinarPractical steps to achieve net-zero underwriting – Set a baseline, define targets and take action
- 03/30/2023
- Live, Online
- 10:00 am - 11:00 am GMT
WebinarPolitics & Policy: Sustainability Measures and Physical Risks
- 03/30/2023
- Live, Online
- 10:00 am - 11:00 am EDT
PLATFORMS
OTHER PRODUCTS
- Research Online
- 451 Research
See All Product Logins

EMA accepts The Medicines Co.'s application for urinary tract infection drug

Insight Weekly: SVB fallout limited; US rents up; renewable natural gas investments flow in

A Cloud Migration Plan for Corporations featuring Snowflake®

Investor Activism Campaigns Hit Record High in 2022

Essential IR Insights Newsletter - February 2023

9 Aug, 2017 | 10:11

EMA accepts The Medicines Co.'s application for urinary tract infection drug

Author Ira Regmi
Theme Healthcare & Pharmaceuticals

The European Medicines Agency acknowledged receipt of The Medicines Company's application for Vabomere to treat complicated urinary tract infections.

The application is backed by data from phase 3 trial. Vabomere was previously known as Carbavance.